David Foster

Biotech startups

[Stockhead @StockheadAU]

.@RaasGroup has maintained a $1.60 per share valuation for @IslandPharma, implying almost 250% upside from its 46 cent share price, as the company builds a Good Manufacturing Practice stockpile of its antiviral Galidesivir.

#ASX #DrugDevelopment $ILA

https://t.co/HDLBxH2aly

[Stockhead @StockheadAU]

Host Tylah Tully sits down with @IslandPharma managing director David Foster to discuss a series of major milestones, including regulatory approval for Galidesivir to be used against Ebola in Africa.

#ASX #DrugDevelopment $ILA

https://t.co/X9as8MFuIx

[Stockhead @StockheadAU]

📈 @IslandPharma has advanced its Galidesivir drug development program by way of an updated Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID).

🔗 https://t.co/R3Y2tKXvRk

#ASX #Investing $ILA

[Small Caps @SmallCapsASX]

Island Pharmaceuticals $ILA expands USAMRIID deal for Marburg dosing optimisation with BSL-4 study; expected to start next quarter, topline in H2 CY2026.

https://t.co/KwDGIC6a7l

[islandpharmaceuticals @IslandPharma]

ICYMI: Island Pharmaceuticals (#ASX: $ILA) receives FDA confirmation on Galidesivir’s Animal Rule pathway, de-risking approval and enabling accelerated progress to pivotal studies. Program eligible for PRV, last valued at ~US$200m. https://t.co/vLwlluMk9a

[islandpharmaceuticals @IslandPharma]

Island Pharmaceuticals (#ASX: $ILA) secures $9m in strategic funding to advance #Galidesivir through FDA Animal Rule pathway, supporting NDA submission and positioning the program for potential US Strategic National Stockpile procurement and PRV upside. https://t.co/bZLmvXAt3B

[Stockhead @StockheadAU]

CEO of @IslandPharma Dr David Foster discusses how they are closing in on FDA feedback for potential Ebola and Marburg treatment https://t.co/Oweu94iNFQ #ASX #DrugDevelopment $ILA

[islandpharmaceuticals @IslandPharma]

Galidesivir transaction completed ahead of schedule
- $ILA finalised #Galidesivir acquisition, a broad-acting #antiviral with over US$70m in US R&D funding. FDA submissions for Marburg expected this quarter, with animal trials anticipated before year-end. https://t.co/wICUYpXbRC

[Stockhead @StockheadAU]

.@IslandPharma has finalised its acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals after completing due diligence ahead of schedule.
#ASX #pharmaceuticals
https://t.co/LW1P7hr7Hy

[islandpharmaceuticals @IslandPharma]

ICYMI: 📢 $ILA welcomes Jason Carroll as Non-Executive Chairman. With 30+ years in life sciences, incl. J&J & Janssen, he brings strong R&D and strategy expertise. A major shareholder, Jason supports ILA’s mission to develop a #denguefever treatment. More: https://t.co/FD6pHoBCF9

[Stockhead @StockheadAU]

Long Shortz with David Foster from @IslandPharma Targeting Ebola, Zika & Marburg with Gallidesivir, watch the interview here: https://t.co/6n0txdhy1V #ASX #Health $ILA

[Stockhead @StockheadAU]

Island Pharmaceuticals fast tracks portfolio expansion with acquisition of Galidesivir for ‘high-priority threat’ viruses, read more now: #ASX #DrugDevelopment $ILA @IslandPharma https://t.co/C5qMAqUR9f

[islandpharmaceuticals @IslandPharma]

📺 Via @InvestorStream_ :
💊 $ILA seals Galidesivir deal from @BioCrystPharma $BCRX
🦠 Broad antiviral backed by US$70M+ govt funding
🇺🇸 FDA Animal Rule path eyed for Marburg virus
💸 PRV in play (worth up to US$150M)
📈 Shares up 7%, 2M traded
#ASX #Biotech

[islandpharmaceuticals @IslandPharma]

ICYMI: 📽 Webinar Replay available: $ILA Non-Executive Chairman Jason Carroll & CEO Dr David Foster presented the company's strategic acquisition of Galidesivir from @BioCrystPharma (NASDAQ: $BCRX). A major portfolio expansion w/ strong R&D backing. Watch https://t.co/SODwos0rvA

[islandpharmaceuticals @IslandPharma]

ICYMI @StockheadAU: #Antiviral drug development company Island Pharmaceuticals is forging ahead after reporting top-line results from its Phase 2a/b PROTECT Trial using ISLA-101 in a human challenge model of #dengue virus infection.

$ILA $ILA.ax #ASXnews
https://t.co/Al6KvKYZVq

[islandpharmaceuticals @IslandPharma]

Pitt Street Research @PSR_Insights published a research note on Island Pharmaceuticals (#ASX: $ILA).

📈 Valuation range: A$0.30–$0.40 per share (vs. current A$0.165).

Read more: https://t.co/wwJ9TPGJnY #antiviraltherapeutics $ILA.ax #ASX #investing #news

[islandpharmaceuticals @IslandPharma]

Q. $ILA's announcement highlights completion of patient dosing in the 2b cohort, which is more focused on treatment outcomes. When do you expect results here and what will be their significance? https://t.co/9Bpuf5sETD #dengue #denguefever #antiviraltherapeutics $ILA.ax #ASX

[islandpharmaceuticals @IslandPharma]

$ILA is pleased to share that all subjects have been enrolled in its ISLA-101 Phase 2b clinical trial in #dengue fever. Initial results expected around April. Full results from the unblinded data of both the Phase 2a & 2b cohorts expected in Q4 FY25 https://t.co/lr9RHAFfhh

[islandpharmaceuticals @IslandPharma]

@IslandPharma’s CEO David Foster talks to @StockheadAU about the company's Phase 2b clinical trial for ISLA-101, a potential treatment for #denguefever.

Watch to learn more about this exciting development in the fight against this debilitating disease: https://t.co/zeK9YX6nFB

[Stockhead @StockheadAU]

Stockhead’s Fraser Palamara sits down with Island Pharmaceuticals CEO and managing director David Foster to get the short end of the long story on the company’s latest news.
https://t.co/YdNtbwAIqm #ASX $ILA @IslandPharma